Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ).
Shanghai Henlius Biotech, Inc. announced the dosing of the first patient in the United States for its international multi-center phase 2 clinical study of HLX43, targeting advanced non-small cell lung cancer. This study, which is also ongoing in China, aims to assess the efficacy and safety of HLX43, with plans to expand trials to Australia, Japan, and other countries. The announcement marks a significant step in the company’s efforts to advance its oncology pipeline and strengthen its position in the global biotechnology market.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$77.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development of innovative antibody-drug conjugates and other biologics for the treatment of cancer and other diseases. The company’s primary products include HLX43, an anti-PD-L1 antibody-drug conjugate, and it has a market focus on advanced/metastatic solid tumors, including non-small cell lung cancer.
Average Trading Volume: 1,360,890
Technical Sentiment Signal: Buy
Current Market Cap: HK$45.03B
Find detailed analytics on 2696 stock on TipRanks’ Stock Analysis page.